Search all ERS
Interstitial Lung Diseases
Respiratory Critical Care
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
ERJ Open Research
European Lung White Book
All ERS guidelines
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
Has the time come to shorten TB treatment and TB preventive therapy?
C. Magis-Escurra (Nijmegen, Netherlands)
Virtual Congress 2021 – Respiratory infections
State of the art session
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Magis-Escurra (Nijmegen, Netherlands). Has the time come to shorten TB treatment and TB preventive therapy?. Virtual Congress 2021 – Respiratory infections
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
No comment yet.
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
On abandon of the tuberculosis treatment
Source: Eur Respir J 2003; 22: Suppl. 45, 522s
Early experience with the implementation of the WHO shorter MDR-TB treatment regimen in Singapore
Source: International Congress 2018 – Drug-resistant tuberculosis
Do we need to screen for latent TB when initiating a methotrexate treatment?
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 589s
A comparison of on-site versus remote physician follow up of directly observed preventive treatment (DOPT) for latent tuberculosis infection (LTBI) on completion rates
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II
Experience of isofon use for therapy and chemoprophylaxis of tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 486s
Should we treat every patient with latent TB? Is there a cost to pay?
Source: International Congress 2018 – Tuberculosis transmission and screening strategies
How did the tuberculosis patients reach to a tuberculosis dispensary and how long did it take?
Source: Annual Congress 2011 - Challenges in tuberculosis control
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment
Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches
Choice and adherence in preventive treatment for tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 523s
Is DOTS-Plus effective and cost-effective?
Source: Annual Congress 2007 - PG18 - New challenges in fighting tuberculosis in Europe
Directly observed therapy versus self administered therapy for patients of new smear positive pulmonary tuberculosis during hospitalisation period
Source: Eur Respir J 2004; 24: Suppl. 48, 723s
Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis?
Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis
A choice of regimen improves completion for patients with latent TB infection
Source: Breathe 2008; 4: 366
The effectiveness of the treatment of patients with TB in the condition adapted DOTS-strategy in Ukraine
Source: Annual Congress 2008 - Outcomes of tuberculosis treatment
How soon does tuberculosis in HIV infected patients respond to anti-tuberculous treatment?
Source: Annual Congress 2010 - Tuberculosis and HIV coinfection
Impact of smoking on outcome of treatment of tuberculosis in patients taking intermittent treatment of tuberculosis under India‘s revised tuberculosis control program
Source: Annual Congress 2008 - Health effects of passive smoking and of a smoking ban
Long term treatment out come in multi drug resistant tuberculosis
Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis